An international collaborative study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a malicious form of a protein that drives the formation of melanoma. The findings, published ...
May 19, 2016
0
10
Based on scientific findings of the Netherlands Cancer Institute, a new combination treatment has been developed for patients with metastatic bowel cancer and a mutation in the BRAF gene. After a clinical trial in over 600 ...
Sep 30, 2019
0
4
The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose tumors had mutations in the MAPK cell-signaling pathway, according to data from a phase I clinical ...
Dec 15, 2017
0
6
Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report.
Apr 9, 2014
0
0
Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors ...
Apr 12, 2024
0
53
Melanoma is the deadliest form of skin cancer, killing more than 8,000 in the U.S. each year. Approximately 40 percent of advanced melanoma tumors are driven to grow by the presence of mutations in a gene known as the BRAF ...
Nov 21, 2013
0
0
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have greatly improved patient ...
Mar 2, 2021
0
12
Patients with advanced or metastatic melanoma have been able to live longer cancer-free lives because of several new therapies approved over the last decade, such as BRAF and MEK inhibitors. However, despite the success of ...
Apr 19, 2018
0
5
Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including ...
Sep 15, 2021
0
34
Half of melanoma patients with the BRAF mutation have a positive response to treatment with BRAF inhibitors, but nearly all of those patients develop resistance to the drugs and experience disease progression.
Feb 24, 2014
0
0
